Translational Genomics Research Institute (TGen)

What Translational Genomics Research Institute (TGen) does

The Translational Genomics Research Institute (TGen) is an Arizona-based nonprofit medical research institute founded in June 2002 and headquartered on the Phoenix Biomedical Campus, with a pathogen genomics division (TGen North) in Flagstaff. Operating as a City of Hope affiliate since 2014, TGen conducts translational genomics research targeting cancer, neurological disorders, infectious diseases, and rare childhood disorders, employing 501-1,000 staff and maintaining five specialized research divisions: Bioinnovation and Genome Sciences, Clinical Genomics and Therapeutics, Early Detection and Prevention, Immunology and Microbiome, and the Scientific Technology Assessment Research Team (START). The institute's mission is to convert genomic discoveries into clinical applications through a portfolio of clinical laboratory services, research service centers, patient programs, and education pipelines.

TGen's core offerings fall into four categories. First, clinical genomic testing through its CAP-accredited, CLIA-certified TGen Clinical Laboratory, including the proprietary JAYseq 72-hour whole-genome sequencing test for multiple myeloma and the ALTseq 48-hour WGS test for acute myeloid leukemia. Second, fee-for-service research platforms including the Collaborative Sequencing Center (NovaSeq X Plus, Revio, PromethION, Onso), the Center for Spatial Multi-Omics (MERSCOPE Ultra, Xenium, Visium HD), the Integrated Mass Spectrometry Shared Resource (proteomics and metabolomics), the Integrated Microbiomics Center, and SOMAmer Plasma Proteomics (measuring 9,000+ proteins from 55 µL samples). Third, patient-facing programs including MindCrowd (an online brain health study with 919,966+ participants), the Center for Rare Childhood Disorders, clinical trials access through City of Hope (400+ trials annually enrolling 6,000+ patients), and the MindCrowd Mobile Brain Health Laboratory. Fourth, education programs including the 20-year Helios Scholars paid internship, Bioscience Leadership Academy, and Ivy Neurological Sciences Internship Program.

The institute operates a hybrid nonprofit revenue model combining philanthropic donations, federal and foundation research grants (notably the NCI P30 Cancer Center Support Grant through City of Hope), clinical laboratory service fees, and sequencing service fees (human genomes from $475 per sample for catalog services). Distribution occurs through direct enterprise sales to healthcare providers for clinical testing, the City of Hope and HonorHealth Virginia G. Piper Cancer Center partnership network for clinical trials, a global research services channel shipping samples to Phoenix, and self-serve citizen science platforms like MindCrowd. Customer segments include cancer and rare disease patients, academic and industry researchers, Arizona-based students, and clinical trial participants, with major philanthropic supporters including the Flinn Foundation, Virginia G. Piper Charitable Trust, Carter Altman Fund, Nason family, Ben and Catherine Ivy Foundation, and the State of Arizona.

Name

Translational Genomics Research Institute (TGen)

Legal name

The Translational Genomics Research Institute

Website

https://tgen.org

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

251–500 employees

Short description

TGen is a Phoenix-based nonprofit medical research institute and City of Hope affiliate conducting translational genomics across cancer, neurological disorders, infectious disease, and rare childhood disorders through clinical genomic testing, multi-omics service centers, patient programs, and bioscience education.

Ownership category

akta.pro rank

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others

Revenue model

1. Philanthropy and Donor Funding: TGen operates as a nonprofit 501(c)(3) research institute (EIN: 75-3065445) primarily funded through charitable donations. Major donor funding includes $16.5 million from the Carter Altman Fund and the Nason family for whole genome sequencing programs. Special funds enable donors to support specific disease research areas.
2. Clinical Laboratory Services: CAP-accredited clinical laboratory providing fee-for-service genomic testing including JAYseq for multiple myeloma and ALTseq for AML. Revenue generated from clinical test processing for healthcare providers and patients.
3. Sequencing Services: Collaborative Sequencing Center provides fee-based genomic sequencing services to academic researchers and industry partners. Human genome sequencing available at costs as low as $475 per sample for catalog services.
4. Clinical Trials Research: Partnership with City of Hope conducts over 400 clinical trials annually enrolling more than 6,000 patients, potentially generating research funding and enabling pharmaceutical partnerships.

Pricing tiers

Go-to-market motion1 record

Distribution channels7 records

Marketing channels9 records

Core offering

TGen is a nonprofit medical research institute that conducts clinical genomic testing and translational research. Through its CAP-accredited clinical laboratory, it offers proprietary rapid whole-genome sequencing tests (JAYseq for multiple myeloma, ALTseq for AML). It also operates specialized research service centers providing sequencing, spatial multi-omics, proteomics, metabolomics, and microbiomics services to researchers and industry partners.

Product overview

TGen (Translational Genomics Research Institute) is an Arizona-based nonprofit medical research institute, part of City of Hope, offering a portfolio of genomic testing services and research platforms. The core clinical products include JAYseq (72-hour whole-genome sequencing for multiple myeloma) and ALTseq (48-hour rapid WGS for acute myeloid leukemia), both performed in TGen's CAP-accredited clinical laboratory. Research service centers provide access to advanced sequencing (Collaborative Sequencing Center), spatial multi-omics (COSMO), proteomics and metabolomics (Integrated Mass Spectrometry), and microbiomics (TIMC) platforms. Patient-facing offerings include the MindCrowd online brain health study, the Center for Rare Childhood Disorders, clinical trials access, and a mobile brain health laboratory. Education programs include the Helios Scholars internship, Bioscience Leadership Academy, and Ivy Neurological Sciences Internship. The institute operates as a platform-plus-services model where genomic testing is the core offering augmented by specialized research service centers and patient engagement programs.

Differentiator

Problem solved

Functional benefit

Brands

• MindCrowd: Free online brain health study and memory test designed to engage users in cognitive research and understand how the human brain ages.
• ALTseq
• JAYseq
• TGen Foundation
• Helios Scholars at TGen
• TGen Bioscience Leadership Academy

Products and services

• JAYseq Clinical whole-genome sequencing (WGS) test specifically designed for multiple myeloma patients. Analyzes all 3 billion base pairs of patient DNA to identify genetic mutations, translocations, and other changes that guide personalized treatment strategies. Ordered by healthcare providers through TGen's CAP-accredited clinical laboratory.
• ALTseq Rapid 48-hour whole-genome sequencing test for patients with acute myeloid leukemia (AML). Provided through TGen's CAP-accredited clinical laboratory for healthcare providers to guide AML diagnosis and treatment.
• Collaborative Sequencing Center

Quantifiable outcome

• JAYseq returns comprehensive genomic results in 72 hours vs. traditional tests taking weeks
• +4 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered flagship, core and minor.

• City of HopeflagshipStrategic or Co-development PartnerTGen is an affiliate of City of Hope, combining genomic research capabilities with state-of-the-art clinical settings. This alliance enables rapid translation of genomic discoveries into patient care. City of Hope provides the clinical environment while TGen contributes genomic expertise, accelerating development of precision medicine.
• Multiple Myeloma Research FoundationcoreStrategic or Co-development Partner15-year collaboration that led to development of JAYseq clinical whole-genome sequencing test for multiple myeloma patients. Foundation funding and partnership supported research leading to rapid genomic profiling capability.
• TD2 OncologycoreStrategic or Co-development PartnerCollaboration on Phase II ketogenic diet trial for metastatic pancreatic cancer published in journal Cancer. TD2 conducted the trial with TGen providing research support.
• Virta HealthminorStrategic or Co-development PartnerPartnership in ketogenic diet trial for pancreatic cancer. Virta Health contributed medical supervision expertise for the medically supervised ketogenic diet component.
• Helios Education FoundationcoreGTM or Marketing PartnerPartnership supporting the Helios Scholars at TGen paid summer internship program. Foundation provides funding and collaboration for bioscience education for Arizona students.
• Virginia G. Piper Cancer Center at HonorHealthcoreChannel Partner/ Reseller/ DistributorClinical Trials Program partnership offering Phase I oncology trials to Phoenix-area patients. TGen leverages this partnership to provide clinical trial options not available elsewhere in the region.
• Northern Arizona UniversityminorStrategic or Co-development PartnerJoint effort with TGen and City of Hope on Microbiome and Immuno-Oncology (MIOC) program combining expertise from multiple institutions for microbiome and cancer research.
• University of ArizonaminorStrategic or Co-development PartnerAcademic partner contributing to MindCrowd brain research initiative alongside TGen, City of Hope, and other institutions.
• Johns Hopkins UniversityminorStrategic or Co-development PartnerAcademic partner contributing to MindCrowd brain research initiative. Part of multi-institutional Precision Aging Network studying memory and brain aging.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Guardant Health: Clinical genomics company specializing in liquid biopsy and tumor sequencing for oncology treatment selection. Comparable in providing rapid, guideline-informed genomic profiling used by oncologists in clinical practice.
• Broad Institute: Nonprofit research institute affiliated with MIT/Harvard that operates large-scale genomic sequencing, clinical genomics, and multi-omics platforms. Directly comparable to TGen as a research-to-clinic genomics institute with similar technology stack and translational mission.
• Foundation Medicine: Clinical genomics company (Roche subsidiary) offering comprehensive genomic profiling for cancer patients through CLIA-certified lab. Directly comparable to TGen's JAYseq/ALTseq clinical WGS tests in serving oncologists with treatment-selection genomic data.
• J. Craig Venter Institute: Nonprofit genomics research institute focused on human, microbial, and synthetic genomics. Comparable to TGen in operating model (nonprofit research institute) and in-house sequencing and bioinformatics capabilities.
• New York Genome Center: Nonprofit genomics research and clinical sequencing center serving academic and industry clients. Comparable to TGen's Collaborative Sequencing Center in providing fee-based sequencing services and translational research collaborations.
• HudsonAlpha Institute for Biotechnology: Nonprofit genomics and clinical diagnostics institute in Alabama operating sequencing, clinical lab, and rare-disease programs. Closely comparable to TGen in operating model (nonprofit research + clinical lab) and disease focus (rare disease, cancer, neurological).
• Tempus Labs: Clinical genomics and multi-omics company providing sequencing, transcriptomics, and AI-driven clinical decision support for oncology. Comparable in offering rapid genomic profiling for cancer treatment selection and large-scale clinical data infrastructure.
• GeneDx: Clinical genomics company specializing in rare disease and pediatric whole-genome sequencing. Directly comparable to TGen's Center for Rare Childhood Disorders in the rare pediatric diagnostic market.

Broad incumbents

• Standard BioTools (SomaLogic): Commercial proteomics platform providing SOMAmer/SomaScan technology that TGen's SOMAmer Plasma Proteomics service center operates. Comparable as the underlying proteomics technology platform leveraged by TGen's clinical and translational research workflows.
• 10x Genomics: Public life-science technology company providing the spatial multi-omics platforms (Xenium, Visium HD) that TGen's COSMO service center runs. Comparable as the underlying platform vendor for TGen's spatial transcriptomics offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• Xx.com/tgen
• YouTubeyoutube.com/@MindCrowd
• Facebookfacebook.com/helptgen
• Pinterestpinterest.com/tgenmindcrowd
• LinkedInlinkedin.com/company/tgen

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries16 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Translational Genomics Research Institute (TGen)